CRIS - キュ―リス (Curis Inc.) キュ―リス

 CRISのチャート


 CRISの企業情報

symbol CRIS
会社名 Curis Inc (キュ―リス)
分野(sector) Health Care   ヘルスケア
産業(industry) Biotechnology: Biological Products (No Diagnostic Substances)  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 キュリス(Curis Inc.)は癌治療薬の開発、商業化を求めるバイオテクノロジー企業である。同社の薬品候補は経口可能なヒストン脱アセチル化酵素(HDAC)の小分子阻害剤CUDC-907、ホスファチジルイノシトール-3-キナーゼ(PI3K)酵素を含む。CUDC-907はクラスI、IIのHDAC、及びクラスIのPI3K酵素の経口二重阻害剤である。CA-170は免疫活性化の負の調節因子として独立して機能するプログラムされた死亡リガンド-1(PDL1)およびT細胞活性化のVドメインIgサプレッサー(VISTA)免疫チェックポイントタンパク質を選択的に標的化するために設計される経口小分子薬物候補である。CA-4948はトール様受容体またはある種のインターロイキン受容体シグナル伝達経路のトランスデューサであるインターロイキン-1受容体関連キナーゼ4(IRAK4)キナーゼを阻害するために設計される経口小分子薬物候補である。   キュ―リスは、癌治療の研究開発に従事する米国企業。社内および共同で研究開発プログラムを行っている。癌薬剤候補は、リンパ腫および多発性骨髄腫治療の「CUDC-907」、固形腫瘍およびリンパ腫治療の「CUDC-427」、高度な基底細胞癌の治療のために承認された薬「Erivedge」がある。   
本社所在地 4 Maguire Road Lexington MA 02421 USA
代表者氏名 James R. McNab ジェームズ・R・マクナブ
代表者役職名 Independent Chairman of the Board
電話番号 +1 617-503-6500
設立年月日 36557
市場名 NASDAQ National Market System
ipoyear ―年
従業員数 55人
url www.curis.com
nasdaq_url https://www.nasdaq.com/symbol/cris
adr_tso
EBITDA EBITDA(百万ドル) -39.14600
終値(lastsale) 1.92
時価総額(marketcap) 63707800.32
時価総額 時価総額(百万ドル) 65.03505
売上高 売上高(百万ドル) 10.53200
企業価値(EV) 企業価値(EV)(百万ドル) 63.11205
当期純利益 当期純利益(百万ドル) -42.89600
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Curis Inc. revenues increased 15% to $4.8M. Net loss decreased 35% to $19.4M. Revenues reflect Royalties increase of 13% to $4.9M Research and development net increase of 58% to -$42K. Lower net loss reflects Research_development Expenses B/F decrease of 42% to $13.9M (expense) Stock-Based Compensation Expense in SGA decrease of 21% to $1.6M (expense).

 CRISのテクニカル分析


 CRISのニュース

   Why Curis (CRIS) Shares Are Surging Today?  2021/05/12 16:59:51 Benzinga
Curis Inc (NASDAQ: CRIS ) shares are surging in reaction to updated data from its ongoing open-label, single-arm, Phase 1/2 study of CA-4948 in patients with acute myeloid leukemia (AML) or high-risk myelodysplastic syndromes (MDS). As of data cut off on February 8, in 15 patients (8 MDS and 7 AML), four objective responses were recorded with signs of hematologic recovery, including: One complete response (CR), … Full story available on Benzinga.com
   Point72 Asset Management established new holdings in Curis Inc  2021/04/01 21:30:30 Investing.com
https://www.investing.com/news/stock-market-news/point72-asset-management-established-new-holdings-in-curis-inc-2464353
   Curis Does Earnings Surprise History Hold Any Clue for Stock market Insights & financial analysis  2021/03/16 03:35:00 Stock Market Daily
Curis announce their quarterly, annual earnings. See the latest EPS estimates. Listen to the conference call and remind yourself by…
   Curis Announces Abstract for CA-4948 Accepted for Presentation at the American Association for Cancer Research Annual Meeting  2021/03/10 21:30:00 PR Newswire
LEXINGTON, Mass., March 10, 2021 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that an abstract for CA-4948, a small molecule IRAK4 inhibitor, has been accepted for…
   Curis to Present at H.C. Wainwright & Co. Global Life Sciences Conference  2021/03/02 13:00:00 PR Newswire
LEXINGTON, Mass., March 2, 2021 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that James Dentzer, President and Chief Executive Officer of Curis, will present a company…
   Point72 Asset Management established new holdings in Curis Inc  2021/04/01 21:30:30 Investing.com
https://www.investing.com/news/stock-market-news/point72-asset-management-established-new-holdings-in-curis-inc-2464353
   Curis Does Earnings Surprise History Hold Any Clue for Stock market Insights & financial analysis  2021/03/16 03:35:00 Stock Market Daily
Curis announce their quarterly, annual earnings. See the latest EPS estimates. Listen to the conference call and remind yourself by…
   Curis Announces Abstract for CA-4948 Accepted for Presentation at the American Association for Cancer Research Annual Meeting  2021/03/10 21:30:00 PR Newswire
LEXINGTON, Mass., March 10, 2021 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that an abstract for CA-4948, a small molecule IRAK4 inhibitor, has been accepted for…
   Curis to Present at H.C. Wainwright & Co. Global Life Sciences Conference  2021/03/02 13:00:00 PR Newswire
LEXINGTON, Mass., March 2, 2021 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that James Dentzer, President and Chief Executive Officer of Curis, will present a company…
   Curis to Present at SVB Leerink 10th Annual Global Healthcare Conference  2021/02/19 13:00:00 PR Newswire
LEXINGTON, Mass., Feb. 19, 2021 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that James Dentzer, President and Chief Executive Officer of Curis, will present a company…
   Curis Does Earnings Surprise History Hold Any Clue for Stock market Insights & financial analysis  2021/03/16 03:35:00 Stock Market Daily
Curis announce their quarterly, annual earnings. See the latest EPS estimates. Listen to the conference call and remind yourself by…
   Curis Announces Abstract for CA-4948 Accepted for Presentation at the American Association for Cancer Research Annual Meeting  2021/03/10 21:30:00 PR Newswire
LEXINGTON, Mass., March 10, 2021 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that an abstract for CA-4948, a small molecule IRAK4 inhibitor, has been accepted for…
   Curis to Present at H.C. Wainwright & Co. Global Life Sciences Conference  2021/03/02 13:00:00 PR Newswire
LEXINGTON, Mass., March 2, 2021 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that James Dentzer, President and Chief Executive Officer of Curis, will present a company…
   Curis to Present at SVB Leerink 10th Annual Global Healthcare Conference  2021/02/19 13:00:00 PR Newswire
LEXINGTON, Mass., Feb. 19, 2021 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that James Dentzer, President and Chief Executive Officer of Curis, will present a company…
   Curis Doses First Patient in Phase 1 Study of CA-4948 in Combination with Ibrutinib in Patients with Relapsed or Refractory Hematologic Malignancies  2021/02/09 13:00:00 PR Newswire
LEXINGTON, Mass., Feb. 9, 2021 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that the first patient has been dosed in its Phase 1 trial evaluating CA-4948, a novel,…

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 キュ―リス CRIS Curis Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)